amorcyte amorcyte amorcyte amorcyte amorcyte
amorcyte amorcyte amorcyte amorcyte amorcyte
amorcyte amorcyte
amorcyte
amorcyte
amorcyte
amorcyte
amorcyte
amorcyte
Amorcyte, Inc. is a therapeutics company pursuing cell-based therapies for cardiovascular diseases.

Amorcyte's primary product, AMR-001 is an autologous stem cell product for the treatment of damaged heart muscle following acute myocardial infarction (AMI).
amorcyte
amorcyte
amorcyte home amorcyte contact us
amorcyte
amorcyte
amorcyte
amorcyte
amorcyte
AMORCYTE COMPLETES PHASE I TRIAL OF STEM CELL THERAPY FOR ACUTE MYOCARDIAL INFARCTION
amorcyte
(Amorcyte) announced today the completion of the phase I clinical trial of its lead product, AMR-001.
amorcyte
HACKENSACK, New Jersey - (April 1, 2008)
amorcyte
amorcytemore
amorcyte
amorcyte
amorcyte
AMORCYTE CARDIAC CELL THERAPY TRIAL COMPLETES SECOND OF FOUR PHASES
amorcyte
Stem cell therapy trial picks up pace with three sites now accruing patients
amorcyte
Hackensack, New Jersey - May 8, 2007
amorcyte
amorcytemore
amorcyte
amorcyte
amorcyte
AMORCYTE CARDIAC CELL THERAPY TRIAL PASSES FIRST STAGE AND OPENS TWO NEW SITES
amorcyte
Stem cell therapy trial proceeds to next stage and opens in two new clinical centers
amorcyte
Hackensack, New Jersey - January 2, 2007
amorcyte
amorcytemore
amorcyte
amorcyte
amorcyte
AMORCYTE SECURES ADDITIONAL FUNDING TO EXPAND CLINICAL PROGRAM IN CARDIOVASCULAR THERAPY
amorcyte
PA Early Stage joins Colt Ventures in expanding Amorcyte’s product program
amorcyte
Hackensack, New Jersey (PRWEB) October 23, 2006
amorcyte
amorcytemore
amorcyte

amorcyte amorcyte
amorcyte amorcyte
amorcyte amorcyte amorcyte
Back to Top
amorcyte amorcyte
amorcyte amorcyte amorcyte amorcyte amorcyte